Meeting
2022 ASCO Quality Care Symposium
Adverse events associated with androgen receptor signaling inhibitors in the treatment of prostate cancer: A systematic review and network meta-analysis.
Authors
Brent Cao
University of Illinois College of Medicine, Chicago, IL
Brent Cao, Melissa Kim, Natalie Marie Reizine, Daniel Moreira
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Patient Safety
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 317)
DOI
10.1200/JCO.2022.40.28_suppl.317
Abstract #
317
Poster Bd #
C24
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Risk of fall and clinical fracture associated with androgen receptor inhibitors: A systematic review and meta-analysis.
First Author: Zin Myint
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu